- Home
- KTTA
as 06-27-2025 10:32am EST
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).
| Founded: | 2020 | Country: | United States |
| Employees: | N/A | City: | MIAMI BEACH |
| Market Cap: | 2.8M | IPO Year: | 2021 |
| Target Price: | N/A | AVG Volume (30 days): | 222.0K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -9.80 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.71 - $7.50 | Next Earning Date: | 08-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Pasithea Therapeutics Corp. News
KTTA Breaking Stock News: Dive into KTTA Ticker-Specific Updates for Smart Investing
GlobeNewswire
18 days ago
Pasithea Therapeutics Appoints Expert in ETS2-driven Inflammatory Disease to Scientific Advisory Board
GlobeNewswire
a month ago
Pasithea Therapeutics Presents Updated Interim Data from Ongoing Phase 1 Study of PAS-004 at the ASCO Annual Meeting 2025
GlobeNewswire
a month ago
Pasithea Therapeutics Announces Preclinical Data that Shows PAS-004 Inhibits ETS2 Signaling, a Key Driver of Inflammation in IBD and Other Large Addressable Market Diseases
Clinical Trials Arena
a month ago
Pasithea to commence Phase I/Ib trial of neurofibromatosis type 1 therapy
GlobeNewswire
2 months ago
Pasithea Therapeutics Announces Initiation of Phase 1/1B Study of PAS-004 in Adult NF1 Patients and Activation of First Clinical Trial Site
GlobeNewswire
2 months ago
Pasithea Therapeutics Announces Closing of $5 Million Public Offering
TipRanks
2 months ago
Pasithea Therapeutics 3.57M share Secondary priced at $1.40
MT Newswires
2 months ago
Pasithea Therapeutics Prices $5 Million Public Offering
Compare KTTA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KTTA Pasithea Therapeutics Corp. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.